|Bid||7.46 x 1100|
|Ask||7.47 x 800|
|Day's Range||7.20 - 7.48|
|52 Week Range||5.34 - 9.95|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.29|
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
RESEARCH TRIANGLE PARK, N.C., May 10, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. In the trial, galidesivir was generally safe and well tolerated. This placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in four single-dose cohorts of 5mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg, with a total of 24 volunteers receiving galidesivir by IV infusion. Drug exposures (Cmax and AUC) at the highest dose were 20,500 ng/mL and 44,600 hr.ng/mL, similar to or greater than drug exposures needed in nonclinical galidesivir treatment experiments in Marburg virus disease and Yellow Fever.
BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
—Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees options to purchase an aggregate of 141,224 shares of BioCryst common stock on April 30, 2019 and May 1, 2019, respectively, as inducements material to each employee entering into employment with BioCryst. The options have an exercise price of $7.43 and $7.28 per share, which is equal to the closing price of BioCryst common stock on each grant date. Each stock option vests in four equal annual installments beginning on the one-year anniversary of its grant date, in each case, subject to the new employee’s continued service with the company.
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C., April 24, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial.
BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
RESEARCH TRIANGLE PARK, N.C., April 01, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Life.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its latestRead More...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
—APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm.
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, into Phase 1 clinical development in the second quarter of 2019 for the treatment of complement-mediated diseases. “Based on its outstanding preclinical profile, with high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, we are excited to advance oral BCX9930 into clinical development,” said Dr. William Sheridan, chief medical officer of BioCryst.
It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and M&A news flow . View more earnings on XBI Now, here are the upcoming week's ...
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare.
BioCryst Pharmaceuticals, Inc. (BCRX) today reported additional topline data from the Phase 2 ZENITH-1 trial, including new data from the 250 mg and 500 mg dose cohorts. Data from the now complete trial confirm previously reported results showing a single dose of oral 750 mg BCX7353 was well-tolerated and superior to placebo (p
RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2018.